Botulinum neurotoxins for use in therapy

Abstract

Disclosed herein are compositions and methods for use in therapeutic procedures.

1 . A method for modifying a previous cosmetic treatment on a human patient, comprising administering by injection a total dose of between about 0.2 ng and about 20 ng of a botulinum neurotoxin serotype E to a patient in the proximity of an area that was previously subject to a cosmetic treatment. 
     
     
         2 . The method of  claim 1 , wherein the botulinum neurotoxin serotype E is a pure about 150 kDa botulinum neurotoxin serotype E. 
     
     
         3 . The method of  claim 2 , wherein the cosmetic treatment is glabellar lines. 
     
     
         4 . The method of  claim 2 , wherein the total dose comprises an amount of between about 2 ng and about 10 ng. 
     
     
         5 . The method of  claim 3 , wherein the total dose is between about 2 ng and about 20 ng of the pure about 150 kDa botulinum serotype E. 
     
     
         6 . The method of  claim 5 , wherein the onset of clinical effect of the treatment is obtained within 24 hours of administration of the botulinum neurotoxin serotype E. 
     
     
         7 . The method of  claim 6 , wherein the clinical effect comprises an investigator-assessed Facial Wrinkle Scale (FWS) grade change at maximum frown from moderate to severe prior to the administration of the botulinum neurotoxin serotype E to none or mild following the administration of the botulinum neurotoxin serotype E. 
     
     
         8 . The method of  claim 5 , wherein the duration of clinical effect of the cosmetic treatment ranges from about 14 days to about 30 days following the administration of the botulinum neurotoxin serotype E. 
     
     
         9 . The method of  claim 5 , wherein about 150 U of the pure about 150 kDa botulinum neurotoxin serotype E is injected into at least one muscle. 
     
     
         10 . A method for administrating a therapeutically effective amount of a neurotoxin to a patient, wherein said neurotoxin dosage is expressed in nanograms (ng). 
     
     
         11 . The method of  claim 10 , wherein said neurotoxin comprises botulinum neurotoxin serotype E. 
     
     
         12 . The method of  claim 11 , wherein said therapeutically effective amount comprises an amount of between about 0.2 ng and about 20 ng. 
     
     
         13 . The method of  claim 11 , wherein the botulinum neurotoxin serotype E is a pure about 150 kDa botulinum neurotoxin serotype E. 
     
     
         14 . The method of  claim 11 , wherein the therapeutically effective amount is between about 0.2 ng and about 20 ng of the pure about 150 kDa botulinum serotype E 
     
     
         15 . A method for minimizing scarring in a human patient in need thereof, comprising administering by injection a therapeutically effective amount comprising between about 2 ng and about 20 ng of a botulinum neurotoxin serotype E to the patient to the patient in the proximity of a wound, wherein the duration of clinical effect of the cosmetic treatment ranges from about 14 days to about 30 days following the administration of the botulinum neurotoxin serotype E. 
     
     
         16 . The method of  claim 15 , wherein the botulinum neurotoxin serotype E is a pure about 150 kDa botulinum neurotoxin serotype E. 
     
     
         17 . The method of  claim 16 , wherein said therapeutically effective amount comprises an amount of between about 2 ng and about 10 ng. 
     
     
         18 . The method of  claim 15 , wherein said therapeutically effective amount comprises about 0.2 ng and about 20 ng of the pure about 150 kDa botulinum serotype E. 
     
     
         19 . The method of  claim 15 , wherein said wound comprises a surgical incision. 
     
     
         20 . The method of  claim 19 , wherein said surgical incision is a result of a cosmetic surgical procedure.